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Abstract
Herpesviral entry is a highly elaborated process requiring many proteins to act in precise conjunction. Neutralizing
antibodies interfere with this process to abrogate viral infection. Based on promoter transactivation of a reporter gene we
established a novel method to quantify herpesvirus entry and neutralization by antibodies. Following infection with mouse
and human cytomegalovirus and Herpes simplex virus 1 we observed promoter transactivation resulting in substantial
luciferase expression (.1000-fold). No induction was elicited by UV-inactivated viruses. The response was MOI-dependent
and immunoblots confirmed a correlation between luciferase induction and pp72-IE1 expression. Monoclonal antibodies,
immune sera and purified immunoglobulin preparations decreased virus-dependent luciferase induction dose-dependently,
qualifying this approach as surrogate virus neutralization test. Besides the reduced hands-on time, this assay allows analysis
of herpesvirus entry in semi-permissive and non-adherent cells, which were previously non-assessable but play significant
roles in herpesvirus pathology.
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Introduction
Herpes simplex virus 1 (HSV-1) and human cytomegalovirus
(HCMV) are members of the Herpesviridae family representing
prototypical a-herpesviruses and b-herpesviruses, respectively.
Both viruses are ubiquitously found with seroprevalence of 50 to
100%. Herpesviruses are complex, enveloped, double-stranded
DNA viruses, which show the remarkable ability to establish
lifelong latency in immunocompetent hosts. Sterile immunity is
never reached. Therefore, the presence of virus-specific antibodies
is not only indicative for former infection events but also for
replication competent virus able to reactivate under stress-full or
immunocompromising conditions. Both viruses are continuously
underestimated due to their often unapparent and subclinical
infection, but account for severe and even fatal infections
especially in immunodeficient individuals but also in apparently
immunocompetent patients [1]. Additionally, HCMV ranges
among the most-frequent, non-heritable, congenital diseases with
intrauterine transmission rates of 30–40% upon primary HCMV
infection during pregnancy [2]. Although a range of prevalence
rates have been reported, recent studies indicate an incidence of
congenital HCMV infection of 0.5–2% [2–4]. Approximately 10%
of HCMV-infected newborns exhibit a symptomatic infection,
which is frequently associated with sensorineural hearing loss and
other sequelae [5]. According to the centers for disease control and
prevention (CDC) approx. 1 in 750 children is born or develops
permanent disabilities caused by HCMV (http://www.cdc.gov/
cmv/facts.htm). Interestingly, incidence of HCMV transmission
and severity of the associated morbidities seem to be reduced
during recurrent episodes compared to primary infections [6–8],
indicating that the adaptive immune response is capable to
mediate some protection to the foetus.
The factors determining whether or not herpesvirus infections
lead to symptomatic complications are incompletely understood.
Studies in mice indicate that antibodies do play an important role
in precluding recurrent mouse cytomegalovirus (MCMV) infection
[9].
Immunoglobulins (Ig) are B-cell-derived, highly specific mole-
cules for binding molecular structures of pathogens. Antibodies are
grouped into the five different subclasses IgA, IgD, IgE, IgG and
IgM, each having specialized functions. Abs function upon
pathogen binding by Fc-receptor-mediated opsonisation, recruit-
ment, activation of immune cells (like NK-cells, macrophages and
B-cells) and triggering of the complement cascade. A minor
fraction of antibodies is able to blunt infections directly by blocking
essential mechanisms of attachment, entry or uncoating of
intracellular pathogens like viruses [10]. These antibodies with
direct antiviral capacity are referred to as neutralizing antibodies
(nAbs).
Although the protection against herpesviruses and the control of
reactivation has been attributed to T-cells, especially cytotoxic
CD8
+-T-cells and to a lesser extend CD4
+ helper T-cells, it has
now become increasingly evident that antibodies are important for
immune control of cytomegaloviruses. It has been shown that the
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e14532therapeutic administration of highly concentrated intravenous IgG
(IVIG) preparations reduces the likelihood of congenital HCMV
disease and thereby protects the foetus [11].
HSV-1 and HCMV are intermittently cytopathic viruses [12]
with a delayed kinetic of nAb response after primary infection. For
both viruses, the overall amount of antibodies measured by ELISA
is not directly predictive for the amount of neutralizing antibodies in
a given individual. In detail, nAbs against HCMV appear first
approximately 13 weeks post primary infection and are continu-
ously measured during reactivation [13,14]. However, the inhibi-
tory function of nAbs, particularly in HCMV infections differ in
their blocking efficiency among different susceptible cell types [15]
due to different neutralizeable protein complexes involved in virus
entry [16]. Hence, assessment of the biological activity of
neutralizing antibodies makes it necessary to perform time-
consuming in vitro neutralization assays using different cell types.
The prerequisite for all HCMV and HSV-1 neutralization
assays described so far are adherent and confluent cell layers of
highly permissive cell types and either virus specific mAbs for
staining of infected cells or direct counting of virus plaques
[3,13,17–19]. In vivo, the route of entry into susceptible cells, and
therefore the neutralizing activity of tested serum, is variable for
HSV-1 and HCMV between different cell types [15,20,21].
Unfortunately, many cell types relevant for viral replication,
transmission and pathogenesis are not suitable for testing using
standard neutralization methods, so that the neutralizing capacity
of antibodies can not be appropriately assessed. Furthermore,
during analysis of borderline-concentrated HCMV-reactive sera in
classical neutralization tests, like conventional micro-neutralization
assays, high concentrations of IgG and serum proteins can cause
an unspecific background stain of the cell monolayer (Reinhard
H., unpublished observation). The routinely used methodology to
test the neutralizing capacity of antibodies against herpesviruses
relies on manual titration of virus and antibody dilutions,
microscopic inspection and individual plaque counting. This
procedure is time-consuming, laborious, error-prone and expen-
sive. It does not allow high throughput approaches to routinely test
large patient cohorts and thus remained a test principle for
specialized laboratories.
Facilitating a promoter/enhancer element which is transacti-
vated upon active herpesvirus infection, leading to expression of a
reporter gene, we established a cheap, fast and easy new test
principle, which allows the analysis of the neutralizing capacity of
antibody preparations against herpesviruses in high-throughput
approaches. The novel assay is not cell type restricted and
generally applicable to a variety of cell types, even to non-adhering
cells. Moreover, there is no need for visualizing infected cells by
virus-specific antibodies and no need for manual plaque counting,
opening new avenues to determine neutralizing antibodies in large
patient cohorts and for large-scale screening approaches to identify
therapeutic antibodies or pharmacologic inhibitors preventing
herpesvirus entry.
Results
pTA vectors contain a herpesvirus responsive element
We observed a strong luciferase induction in cells transiently
transfected with commercially available interferon-reporter con-
structs (pTA-GAS) upon infection with HCMV. Unexpectedly,
similar luciferase expression was obtained from the corresponding
control plasmid lacking the IFN-inducible promoter elements
(pTA-Control) (Fig. 1a). In human MRC-5 lung fibroblasts both
vector constructs (pTA-Control and pTA-GAS) were activated
upon infection with three different HCMV strains, i.e. HCMV-
AD169, HCMV-Towne and the endotheliotropic strain HCMV-
TB40/E (Fig. 1a), suggesting that the vector backbone serendip-
itously contains a cytomegalovirus-responsive element. The virus-
mediated activation resulted in a highly significant 1250- to 7000-
fold luciferase induction (p=0.0051 upon HCMV-AD169 infec-
tion of pTA-Control transfected cells). As expected, the IFN-c-
reporter-construct (pTA-GAS), but not the corresponding control
plasmid (pTA-Control), was significantly induced upon treatment
with IFN-c (500 U/ml for 5 h) in mock-infected cells (Fig. 1a).
The virus-specific response clearly exceeded the activation
observed upon IFN-c treatment (.1250-fold activation compared
to ,2.7-fold activation). Nevertheless, we used the control plasmid
(pTA-Control), which is devoid of any additional promoter/
enhancer elements, to preclude composite responses. The HCMV-
specific response was in none of the cases significantly further
increased upon treatment with IFN-c (all t-test results .0.15)
(Fig. 1a), which might be due to the well-described HCMV-
encoded inhibition of Jak-STAT signalling [22,23] or due to the
fact that the virus-induced activation already reached saturating
responses.
The herpesvirus responsive element responds to
different herpesviruses in different cellular contexts
In addition to responding to HCMV, increased luciferase
expression upon infection of NIH3T3 cells with mouse cytomeg-
alovirus (MCMV) was evident in a virus dose-dependent manner
with both constructs (with or without an IFN-inducible promoter
element), while only baseline luciferase expression was seen in
mock infected cells (data not shown). Furthermore, HSV-1, an a-
herpesvirus, induced luciferase activity in infected cells carrying a
reporter constructs (Fig. 1b). Thus, this system was not limited to
assessment of HCMV infection but responds to different types of
herpesviruses. Furthermore, different cells of widely different
origins mounted a significant signal upon infection (Fig. 1b). HSV-
1, but not HCMV, induces luciferase expression in human Jurkat
T-cells (Fig. 1b) confirming previous results, which revealed that
HSV-1 is capable to enter T-cells [24]. In conclusion, this assay is
adaptable to a wide range of target cells and it is not even limited
to adherent cell lines but can be adapted to cells that grow in
suspension.
The herpesvirus responsive element is induced IFN-
independently
Since it is well established that HCMV infection induces type I
IFN (IFN-a/b) [25], we wondered whether the observed
activation is the consequence of type I IFN induction. Especially
the activation of the transcription factor IRF-3 is both hallmark
and prerequisite for type I IFN induction. HCMV induce the
formation of IRF-3 homodimers and the induction of IFN-b
transcription (Fig. 1c). UV-inactivated HCMV induced an even
more prolonged and increased IRF-3 activation and IFN-b
transcription (Fig. 1c), likely due to the absent expression of
virus-encoded inhibitors of IFN induction. We therefore tested
whether the activation is also induced by UV-inactivated HCMV
virions. As shown in Fig. 1b, UV-inactivated viruses did not
activate the reporter construct. Thus, IFN-b and downstream
signalling events can be excluded as potential activators because
both, replication competent and UV-inactivated virus, induce
IFN-b (Fig. 1c) but only the former induce increased luciferase
expression.
Both HCMV and HSV-1 activated the reporter construct to
induce luciferase in CV-1, Vero and ARPE-19 cells indicating that
the activation is not cell type specific, although the expression of
Luciferase-Based Entry Assay
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to ARPE-19 cells (Fig. 1b). Induction of luciferase by HCMV in
Vero and CV-1 cells indicates that the assay principle is applicable
to semi-permissive cells, because HCMV does not replicate in
these cells. Since Vero cells harbour a deletion of the genes
encoding for type I IFNs [26], the results obtained with Vero cells
rule out an involvement of type I IFN genetically, consistent with
the conclusion drawn above.
Episomal vectors harbouring the promoter/enhancer
element confer specific herpesvirus responsiveness
To allow establishment of stable cell lines harbouring the
herpesvirus-responsive element, we sub-cloned the luciferase gene
together with the corresponding promoter from the pTA-Control
vector into a bovine papillomavirus-derived episomal vector
(pB45Neo) [27]. Upon transient transfection of this vector
(pB45Neo-promLUC) into HeLa cells, infection with HSV-1
induced luciferase expression (Fig. 2a). Clonal M2-10B4 cell lines
harbouring pB45Neo-promLUC (selected by G418/geneticin) also
responded to HSV-1 infection with robust luciferase induction
(Fig. 2b).
To analyze if the observed response is NF-kB-, PKC- or Ca
2+-
flux-dependent, we treated cells with either tumour necrosis factor
(TNF)-a, interleukin (IL)-1b, phorbol-12-myristate-13-acetate
(PMA) or ionomycin (Iono) and compared the responses to
induction elicited by HSV-1 infection (Fig. 3a). To document the
biologic activity of the used compounds, cells transiently
Figure 1. Herpesviruses transactivate the pTA-luc plasmid series. (A) Human MRC-5 cells, transiently transfected with the pTA-Control
plasmid (left panel) or pTA-GAS (right panel), were split into aliquots and seeded. Cells were infected with 1 PFU/cell HCMV-AD169, HCMV-Towne,
HCMV-TB40/E (black bars) or left uninfected (white bars). After 24 h the cells were treated for additional 5 h with 500 U/ml human IFN-c. Cells were
lysed and luciferase activity was measured. The experiment was performed in triplicate and the arithmetic mean with the standard deviation is
shown. The significance was tested with the Student’s t-test: * p,0.05 and ** p,0.01. (B) ARPE-19, CV-1, Vero and Jurkat cells were transfected with
2.5 mg pTA-Control plasmid using the Lonza nucleotransfection system. Cells were split so that parallel measurements and infections originated from
the same transfection. 20 h post transfection cells were left uninfected (mock; open bars) infected with 3 PFU/cell HCMV-AD169, HSV-1 F strain (black
bars) or UV-inactivated virus (hatched bar) for additional 20 h. Cells were lysed and luciferase activity was measured. (C) MRC-5 cells were infected
with 3 PFU/cell HCMV-AD169 or UV-inactivated HCMV-AD169. After the indicated time cells were lysed and total RNA or protein was prepared.
Protein lysates were subjected to native sodium-deoxycholate-PAGE for the analysis of IRF-3 dimerization or to SDS-PAGE for the analysis of pp72-IE1
and b-actin protein amount. Proteins were transferred to filters and probed with the indicated antibodies. IFN-b and GAPDH mRNA was assessed by
semi-quantitative RT-PCR from total RNA as. For GAPDH two log10 dilutions were used as template to confirm measurement in the linear
amplification range.
doi:10.1371/journal.pone.0014532.g001
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construct were conditioned in parallel. TNF-a, IL-1b and PMA/
Iono induced luciferase expression from the NF-kB reporter but
none substantially induced luciferase from either the pTA-Control
or the pB45Neo-promLUC construct (Fig. 3a), indicating that
HSV-1 infection induces luciferase by an alternative signalling
mechanism.
Furthermore, no luciferase induction was observed upon
infection with adenovirus (data not shown), the rhabdovirus
vesicular stomatitis virus (VSV) (Fig. 3b) or the c-herpesvirus
Epstein-Barr-virus (Fig. 3c).
HCMV and HSV-1 induce luciferase expression with
differential kinetics
We measured luciferase induction at different time points post
infection with HSV-1 and HCMV. HCMV induced luciferase
starting 8 h post infection, whereas HSV-1 induced luciferase
already 4 h post infection (Fig. 4). Interestingly, we observed
differences concerning the luciferase induction in the presence of
phosphonoacetic acid (PAA), an inhibitor of herpesviral genome
replication and accompanying late gene expression: HSV-1
induced increased amounts (,2-fold 24 h post infection) of
luciferase upon PAA treatment, whereas the HCMV-dependent
response was diminished (,4-fold 24 h post infection) upon PAA
treatment (Fig. 4). We concluded that the transactivation is
mediated by an early/late gene product in the case of HCMV but
by an immediate early or strict early gene product in the case of HSV-
1 (which is increasingly expressed in the absence of the feed-back
inhibition by later gene classes – a regulative circuit which has
been described previously [28]). The presented data indicate that
the test principle is applicable during the entire viral life cycle and
can be measured as early as 4 h and 8 h post infection with HSV-1
and HCMV, respectively.
The reporter gene promoter in the pTA vector is
transactivated
In general, two explanations for the increased luciferase
expression are conceivable: (i) a virus-induced increase in plasmid
number per cell or (ii) an increase in reporter gene expression per
plasmid. The infection could significantly increase the number of
plasmids per cell by either activation of the otherwise bacteria-
specific origin of replication or by significantly increasing
Figure 2. The episomal vector pB45Neo-promLuc confers herpesvirus responsiveness. (A) HeLa cells were transiently transfected with the
pB45Neo-promLUC construct by nucleofection. Cells were infected with HSV-1 F strain (0.5 or 3 PFU/cell) or left uninfected. Cells were lysed and
luciferase activity was determined. (B) G418-selected stable M2-10B4 cell clones (#1, #3 and #4) were infected with 5 PFU/cell HSV-1 F strain for
16 hours. Cells were lysed and luciferase activity was determined.
doi:10.1371/journal.pone.0014532.g002
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blotting if transfected cells, which have been additionally infected,
harbour more plasmid DNA than uninfected cells after transient
transfection. We did not observe an increase of cellular pTA-
Control amount upon HSV-1 infection, but a robust increase in
luciferase expression in the same cells (Fig. 5a). We concluded that
herpesviruses induce an increase of luciferase expression per
plasmid by bona fide transactivation of the otherwise silent minimal
promoter upstream of the luciferase gene.
Sub-cloning of the firefly luciferase gene together with 178
nucleotides (using a vector intrinsic NotI restriction site) of the
upstream minimal promoter element into other vectors transferred
the inducibility upon infection, indicating that this region harbours
the transactivatable genetic element (data not shown). The
subcloned fragment of the pTA-Control plasmid harbours two
genetic elements, which could potentially affect expression: a
transcriptional pause site and the minimal promoter. To
distinguish these, we further truncated the promoter to 38 nts in
front of the transcription start side using an intrinsic NheI-site. This
promoter retained the ability to respond to HSV-1 (see data with
pB45Neo-promLUC). Interestingly, the minimal promoter itself
uses a TATA-box derived from the HSV-1 thymidine kinase (tk) gene,
which has been shown to be significantly induced in transfected
cells by HSV super-infection [29,30]. To test the requirement of
viral gene expression for transactivation, we exploited a well-
known schema. Conditioning of the cells with the reversible
translation blocker cycloheximide (CHX) only allowed transcrip-
tion of immediate early mRNAs. Upon replacement of CHX by
the RNA-polymerase II inhibitor actinomycin D (ActD) immedi-
ate early mRNAs, which have been transcribed in presence of
CHX, become selectively translated. The absence of luciferase
expression under such a regime (Fig. 5b), in conjunction with the
results obtained upon UV-irradiation of the virus, indicated that
viral gene expression is essential for luciferase expression. We
Figure 3. Specificity of responsiveness of the pTA-Control and the pB45Neo-promLUC construct. (A) HeLa cells were transiently
transfected with 2 mg of the ‘66 kB-Luc’ NF-kB-reporter construct, the pTA-Control or the pB45Neo-promLUC. 16 h later cells were treated with
20 ng/ml tumour necrosis factor (TNF)-a, 5 ng/ml interleukin (IL)-1b, 0.1 mg/ml phorbol-12-myristate-13-acetate (PMA) or 1 mg/ml ionomycin (Iono) or
both (PMA/Iono) for 4.5 h. A 16 h infection with 10 or 1 PFU/cell HSV-1 F strain (HSV 1 and HSV 10, respectively) served as control for inducibility by
herpes viruses. (B) HeLa cells were transiently transfected with the pTA-Control or the pB45Neo-promLUC construct and infected with 0.1, 1 or 10
TCID50 vesicular stomatitis virus (VSV) and 0.1, 1 or 10 PFU/cell HSV-1 F strain, respectively. 15 h later cells were lysed and luciferase activity was
measured. (C)1 0
6 RPMI8866 cells were transfected with 2 mg of the pTA-Control construct and infected over night with the indicated EBV genome
copies/cell. Cells were lysed and luciferase activity was determined.
doi:10.1371/journal.pone.0014532.g003
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tk-gene promoter element which is transactivated upon presence of
de novo expressed viral transactivator proteins.
HCMV and HSV-1 induce reporter gene expression MOI-
dependently
To evaluate the potential value of this luciferase-based
transactivation assay for the quantification of virus entry, we used
serial dilutions of HCMV and HSV-1 over a wide range of
infectious doses and analyzed the induced luciferase. Infection
resulted in a virus dose-dependent luciferase expression spanning
at least 2 orders of magnitude at early time points post infection
(Fig. 6) and 3–4 orders of magnitude at later time points (data not
shown). As expected, the system started to became saturated upon
infection with higher MOIs (Fig. 6). We measured the viral
reporter gene induction at early time points (4 and 8 h post
infection with HSV-1 and 14 and 24 h post infection with HCMV)
and observed a clear dose-response correlation. The assay was
applicable to HSV-1 F-strain and a clinical HSV-1 isolate, which
has been only passaged once in cell culture before the usage in this
experiment (Fig. 6b – grey bars).
Promoter transactivation can be exploited to measure
virus neutralization
Since UV-inactivated HCMV and HSV-1 were not able to
induce luciferase expression we concluded that the induction is
due to a virus-dependent transactivation which requires viral gene
expression. These findings prompted us to analyze whether virus
neutralization of HCMV and HSV-1 by a commercially available
IVIG preparation, CytotectH (Biotest, Dreieich, Germany), is able
to block transactivation. As shown in Fig. 7 the transactivation was
again not detectable upon mock infection (white bars) or treatment
with UV-inactivated HCMV (hatched bars). Infection with a
replication competent HCMV or HSV-1 resulted in pronounced
transactivation and luciferase expression. Pre-incubation with a
non-immune serum pool (grey bars) did not decrease the virus-
Figure 4. Time course of luciferase induction upon infection
with HSV-1 and HCMV. MRC-5 cells were transfected with the pTA-
Control plasmid by nucleofection and subsequently infected with
HCMV-HB5 or HSV-1 F strain (4 PFU/cell). PAA was added at the time
point of infection. Cells were lysed at indicated time points post
infection and luciferase activity was measured.
doi:10.1371/journal.pone.0014532.g004
Figure 5. HSV-1 induces a bona fide transactivaion of the pTA-Control promoter. (A) Vero cells were transfected with the pTA-Control
plasmid. The cells were split and infected with HSV-1 F strain. 24 h p.i. the expressed luciferase activity was measured. The cells were lysed and DNA
was extracted in parallel, separated on an agarose gel and used for a Southern blot. The membrane was probed with DIG labelled (DIG high prime,
Roche) pTA-Control plasmid. (B) CV-1 cells were transfected with 700 ng of the pTA-Control vector. Cells were infected with 10 PFU/cell HSV-1 F
strain. Cells were incubated for 4 h with cycloheximide (CHX), which was replaced by 5 mg/ml actinomycin D (ActD) 4 h p. i. for selective immediate
early protein expression conditions. Absence of ActD following washing (fifth bar f. l.) documents reversibility of CHX and continuous CHX and ActD
treatment served as control for drug efficacy. Cells were lysed and luciferase activity was determined.
doi:10.1371/journal.pone.0014532.g005
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PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e14532dependent transactivation, whereas pre-incubation with increasing
concentrations of IVIG (black bars) neutralized transactivation
dose-dependently, indicating that viral entry is a prerequisite for
transactivation of the reporter construct-driven luciferase expres-
sion. Taken together, these results qualify this novel approach as a
suitable surrogate assay for the determination of herpesvirus
neutralization. Human sera of 7 HSV-1 seropositive individuals
(#P1–#P7) and 7 seronegative individuals (#N1–#N7) docu-
mented a clear applicability for clinical sera: All 7 seropositive
donors showed highly statistical significant neutralization of
luciferase activity at 1/10 and 1/20 serum dilutions, whereas
none of the seronegative donors showed signs of neutralization
(Fig. 7c). One donor (#P6) showed significant neutralizing
capabilities even at 1/100 serum dilutions.
To validate the new test principle, we compared the virus-
dependent transactivation with the expression of the HCMV
protein pp72-IE1 measured by immunoblot after antibody-
mediated virus neutralization. pp72-IE1 is expressed with
immediate early kinetics upon infection and is not part of the
HCMV particle and therefore constitutes a marker for successful
HCMV entry and initiation of gene expression. As shown in Fig. 8a,
UV-treatment of virus precluded luciferase expression and de novo
pp72-IE1 expression. Non-immune serum did not decrease the
reporter gene expression, whereas pre-incubation with IVIG
effectively neutralized viral entry and gene expression. A strong
correlation between luciferase activity and pp72-IE1 protein amounts
- detected in the same lysate - became evident. These results validate
that the luciferase induction constitutes an easy and quantitative
surrogate for viral entry and subsequent gene expression.
To correlate the results obtained with the newly established
luciferase-based neutralization test with classical micro-neutraliza-
tion tests, we determined the neutralizing titer of IVIG in both
assay systems simultaneously. As shown in Fig. 8b, both test
systems gave almost congruent dose-response curves finally
resulting in comparable 50% virus neutralization titers. Such a
consistency between our newly established assay and a classical
neutralization test was also observed upon HCMV neutralization
(data not shown).
Figure 6. pTA-Control is transactivated upon herpesvirus infection in a virus dose-dependent manner. (A) WI-38 cells were transiently
transfected (nucleofection) with the pTA-Control plasmid. Cells were infected for 14 h (left panel) or 24 h (right panel) with indicated PFU/cell HCMV-
TB40/E. Cells were lysed and luciferase activity was measured. The arithmetic mean of triplicates 6 standard deviation (SD) is shown. Statistical
significance was tested by unpaired two-sided t-test with unequal variance compared to the mock (black asterisks) and the corresponding lower
infectious dose (depicted in grey). * p,0.05; **p,0.01 and *** p,0.001. Please note the different scale between left (*10
4) and right (*10
5) panel. (B)
As in (A) but HeLa cells were nucleofected with pB45Neo-promLUC and infected with the indicated infectious dose of HSV-1 F strain (black bars) or a
low-passage clinical HSV-1 isolate (grey bars). Arithmetic mean of triplicates 6 SD is shown. p-values as in (A).
doi:10.1371/journal.pone.0014532.g006
Luciferase-Based Entry Assay
PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e14532Since MCMV also transactivates the promoter, we compared
the neutralizing capacity of MCMV immune serum and non-
immune serum derived from isogenic inbred mice. We observed
clear neutralization by immune serum at 1/10 and 1/25 serum
dilutions, but not with non-immune serum, for two infectious doses
(1 PFU/cell and 0.1 PFU/cell). Additionally, we compared our
assay approach with neutralization test principles comprising
luciferase-expressing MCMV and GFP-expressing MCMV. All
three assays gave comparable results (Fig. 8c).
Having demonstrated the applicability for clinical HSV-1
isolates (Fig. 6b), we tested neutralization capacity of an
‘autologous’ serum-virus-pair from the same donor. We observed
dose-dependent virus neutralization of reporter gene transactiva-
tion. Such a test might be of particular advantage since isolate/
strain-specific neutralizing antibodies have been documented for
HCMV gN [31]. These antibodies might now become easily
assessable.
Physicochemical parameters of HCMV entry and
neutralization
Facilitating our novel assay, we analyzed the impact of the
parameters acidity (pH), osmolarity, temperature and incubation
time on HCMV infectivity and virion neutralization. We chose an
approximately half-maximal neutralizing IVIG concentration to
analyze whether neutralization is increased or decreased. We
incubated HCMV in presence or absence of IVIG prior to
infection under the indicated conditions and subsequently infected
cells maintaining the three remaining parameters as used under
standard conditions (1.5 h incubation, 37uC, 340 mOsm, pH 7.4;
indicated by grey shading). We focussed on a range of parameters,
Figure 7. Virus-induced transactivation can be neutralized using IVIG. (A) MRC-5 cells were transfected with 2 mg pTA-Control plasmid
using the Lonza transfection protocol and reagents. Cells were infected at different PFU/cell (10; 5; 2; 0.5 or 0.1 PFU/cell) of infectious HCMV-HB5
(black bars), UV-inactivated HCMV-HB5 (hatched bar) or left uninfected (white bar). Virus was incubated with indicated dilutions of the IVIG
preparation CytotectH for 1 h at 37uC before infection. As control the virus was incubated with the pooled sera of two seronegative donors (grey bar).
(B)A si n( A), but CV-1 cells were used and infected with HSV-1 strain F (2 PFU/cell). (C) 5 PFU/cell HSV-1 F strain was incubated for 90 min at 37uC
with 1/10, 1/20 or 1/100 vol/vol dilutions of 14 human sera. #N1–#N7 HSV-1 seronegative donors and #P1–#P7 HSV-1 seropositive donors.
pB45Neo-promLUC transfected HeLa cells were infected with virus-serum suspensions. 20 h post infection cells were lysed and luciferase activity was
determined.
doi:10.1371/journal.pone.0014532.g007
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physiologic conditions. As shown in Fig. 9, acidity (pH 6–10),
osmolarity (340–540 mOsm) and temperature (25–45uC) did not
have a significant impact on virus neutralization. Increasing
temperature reduced viral infectivity antibody-independently
(Fig. 9c). Osmolarity had, at least under these experimental
conditions, only limited impact on HCMV infection and
neutralization (Fig. 9d). The pH seems to affect infectivity
irrespective of antibodies and basic conditions (pH.8.5) seem to
be more detrimental for HCMV than neutral and weak acidic
conditions (Fig. 9b). Reducing the pH to 4 clearly damaged viral
integrity, even in absence of antibodies, although statistically
significant neutralization could still be observed. At pH of 3 or
lower no viral transactivation was observed (see insert graphic of
Fig. 9b).
Although the intrinsic HCMV stability at 37uC is limited
(Fig. 9a), the incubation time between virus and antibody
significantly affects neutralization: Incubating the virus without
antibodies for 8 hours, 4 hours, 30 min, 15 min or 10 min did not
resulted in significant changes in infectivity compared to standard
Figure 8. Comparison of new test principle with established methodology. (A) MRC-5 cells were transiently transfected (Lipofectamine)
with pTA-Control plasmid. Cells were split and seeded before mock-infection or infection with UV-inactivated HCMV-HB5 or HCMV-HB5. Virus had
been incubated with a 1/50 dilution of negative human serum (NS; grey bar), no serum or with the indicated dilutions of the IVIG preparation
CytotectH (black bars) for 1 h at 37uC. 20 h p. i. cells were lysed and luciferase activity was measured. An aliquot of the same lysates was separated by
sodium-dodecylsulfate-PAGE. The proteins were transferred on filters and probed with pp72-IE1 and b-actin specific antibodies. (B) Comparison of
the newly established luciferase-based neutralization test with a classical neutralization test. For the classical neutralization test, serial dilutions of
CytotectH were incubated for 1.5 h with 2 PFU/cell of the HSV-1 strain F prior to infection of CV-1 cells. 36 h p.i. plaques were counted. The mean of
quadruplet values 6 SD is shown. For the luciferase-based NT CV-1 cells were transiently transfected (Lipofectamine 2000 CD) with pTA-control
plasmid, split and seeded. 2 PFU/cell of the HSV-1 strain F were incubated for 1.5 h with serially diluted CytotectH before infecting CV-1 cells. 20 h p. i.
the cells were lysed and luciferase activity was measured. The neutralization titer is determined as serum dilution able to mediate 50% virus
neutralization. (C) Primary embryonic mouse fibroblasts were transfected by nucleofection with pTA-Control plasmid or left untransfected. wt-MCMV
Smith strain, MCMV:gfp or Dm157-MCMV:luciferase were incubated for 90 min at 37uC with 1/10 (v/v) or 1/25 (v/v) dilutions of mouse (BALB/c)
MCMV-immune serum or the control non-immune serum. Cells were infected with these suspensions. 16 h later cells were lysed for the
determination of luciferase activity in the case of untransfected cells infected with Dm157-MCMV:luciferase and the pTA-Control transfected cells
infected with wt-MCMV. GFP-positive cells were determined by FACS for MCMV-gfp. The relative neutralization of the input virus is depicted. (D)5
PFU/cell HSV-1 F strain or a low-passage clinical HSV-1 isolate were incubated for 90 min at 37uC with indicated dilutions of the autologous human
serum derived from the individual the virus was isolated from. 16 h later cells were lysed and luciferase was determined.
doi:10.1371/journal.pone.0014532.g008
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times (30, 15 and 10 min) decreased neutralization and prolonged
incubation (to 4 or 8 hours, indicated by arrows) increased
neutralization, respectively. We therefore suggest prolonging the
incubation time to 4 or 8 hours (but not longer), especially for sera
with borderline concentrations of neutralizing antibodies.
The novel approach allows assessment of virus
neutralization in non-adherent and semi-permissive cells
The neutralization results obtained so far, using the IVIG
preparation, prompted us to extend the assay application. We
analyzed if well described neutralizing monoclonal antibodies
against HCMV and HSV-1 are also able to block luciferase
expression. The human monoclonal antibody ITC-88 (IgG1),
directed against the AD-2 domain of the HCMV glycoprotein B
(gB), a target of neutralizing antibodies during HCMV infection,
has been shown to have neutralizing capacity [32]. Incubation
with this nAb abrogated HCMV-induced luciferase expression
(Fig. 10a). In a parallel set of experiments, neutralization by the
HSV-1 gD specific monoclonal antibody HD-1 (IgG2a) [33] was
assessed. Again the virus-induced luciferase expression was clearly
neutralized. Altogether, these results confirm the usability of our
novel luciferase-based reporter assay as neutralization test
principle.
The reduced hands-on time and the objective read-out principle
alone would already justify the use of the novel luciferase-based
system to measure neutralization, but additionally, our results
demonstrate, that the assay principle allows analysis of HSV-1
entry in non-adherent Jurkat cells. Classical neutralization assays
are hardly applicable to suspension cells because neither plaque
titration nor staining of infected cells can readily be performed.
Since our test principle is neither restricted to adherent nor
confluent cell layers which allow plaques formation upon infection,
we surmised that our test principle would allow neutralization
Figure 9. Neutralization test under different physicochemical parameters. MRC-5 cells were transiently transfected (nucleofection) with
pTA-Control plasmid. 3 PFU/cell HCMV-TB40/E were incubated for 90 min at 37uC (or as indicated otherwise) with a 1/40 dilution of IVIG CytotectH
(red triangles) or antibody-free medium (black dots). After this incubation MRC-5 cells were infected. Luciferase induction was assessed one day post
infection. Results are depicted as fold response compared to maximum response to allow comparison of the six independent experiments. (A) Effect
of virus-antibody incubation time. (B) Impact of acidity (pH) on neutralization. Media was buffered to the indicated pH value by addition of HCl or
NaOH, respectively. Arrows indicate time points (4 and 8 h) where intrinsic stability is not affected but neutralization is enhanced. An insert shows the
neutralization at acidic conditions (pH 2–7). (C) Impact of temperature on neutralization during virus-antibody incubation. (D) Grading increase in
osmolarity (by addition of NaCl; whereby 1 mM NaCl was calculated as 2 mOsm due to dissociation of ions) on neutralization. Standard conditions are
shaded in grey. Statistically significant (two-tailed paired t-test) differences from these conditions are indicated by asterisks.
doi:10.1371/journal.pone.0014532.g009
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we tested if HSV-1 can be neutralized by the monoclonal antibody
HD-1 in Jurkat cells. Significant transactivation was induced upon
HSV-1 infection (p,0.013) but not by UV-inactivated HSV-1.
The transactivation was abrogated upon treatment with the
monoclonal antibody HD-1 (Fig. 10b). This result demonstrates
that this new test system allows for the first time the quantitative
analysis of neutralizing capacity of monoclonal antibodies, IVIG
and patient sera in non-adherent and semi-permissive cells.
Discussion
We observed significantly increased luciferase expression of cells
transiently transfected with commercially available constructs
initially designed to investigate Jak-STAT-mediated IFN signalling
upon infection with different herpesviruses. This response was
evident even with the otherwise silent control plasmid harbouring
only a minimal promoter element.
The described assay principle facilitates herpesvirus-induced
transactivation of a reporter construct to quantify virus entry and
gene expression. The transactivation is measured by firefly
luciferase expression after transfection of the reporter construct
but other reporter genes could also be used. The inducibility was
independent of the transfection protocols (data not shown). We
show that the transactivation is not due to IFN induction but is a
direct consequence of the entry of replication competent a- and b-
herpesviruses (Fig. 1). The treatment with UV-inactivated virus
was not sufficient to transactivate the promoter (Fig. 1), indicating
that viral gene expression is necessary and that the transactivating
principle is virus-encoded and not a cellular response to infection.
Our data indicate that the promoter is transactivated by an
immediate early or early gene product encoded by HSV-1 and by an
early/late gene product of HCMV (Fig. 4).
The new assay allows quantitative and sensitive detection of
herpesvirus infections over a large range of at least 2 orders of
magnitude early after infection (and 4 orders of magnitude later
post infection) and in a variety of different cell types - like MRC-5,
Jurkat, Vero, CV-1, ARPE-19 (Fig. 1C) and NIH3T3 cells (data
not shown) from different tissues (lung fibroblasts, T-cells, kidney
cells and epithelial cells) and different species (Homo sapiens,
Cercopithecus aethiops and Mus musculus). The reporter construct
responded to different herpesviruses (HSV-1, HCMV and
MCMV) and gave similar results when comparing different
HCMV strains (HCMV-Towne, HCMV-HB5, HCMV-AD169
and HCMV-TB40/E) (Fig. 1a). The transactivation was blocked
by IVIG preparations (Fig. 6–9), immune sera (Fig. 7c & 8d) and
specific monoclonal antibodies (Fig. 10), but not by non-immune
sera (Fig. 7 & 8), demonstrating that viral entry is a critical
requirement for the transactivation. Therefore, the transactivation
is a surrogate marker for successful viral entry and productive
infection. Whether such a promoter element would also become
transactivated upon reactivation from latency might constitute an
interesting future issue.
Classical virus entry and neutralization assays are time-
consuming and laborious, since a fixed number of plaque-forming
virus particles is incubated with the blocking reagent (i.e. an
antibody,serumordruginhibitor)and thandilutionsaretransferred
to permissive cells (usually highly permissive fibroblasts) to measure
to which extent the treatment significantly reduces the number of
plaques. Since the methods per definition operate with low
countable virus/plaque numbers they are prone to handling errors
and have large standard deviations making it necessary to measure
large datasets to reach statistical significance. An obvious intrinsic
disadvantage of such protocols is that they require virus plaque
counting. Although automated plaque counting systems have been
invented [17] they have not found their way into standard
diagnostic laboratories. The plaque counting is not only time-
consuming and laborious, requiring long hands-on time of trained
personal, but is also very slow. Plaque formation of slow growing
viruses like HCMV requires 6–8 days and even longer when
analysing clinical HCMV isolates. Our method requires all together
,24 h with a limited hands-on time and can even be reduced to 4–
8 hours when stable transfectants are used.
Usual protocols comprise immunostaining procedures to
specifically recognize virus protein producing cells before readable
plaques are formed, but these protocols also take at least 3 days
(from cell seeding to staining and plaque or foci counting) in the
case of HCMV until results can be obtained and are therefore not
as fast as our new approach and require even more hands-on time
due to the staining procedure.
Future applications for this assay procedure will be to test
antibody preparations and monoclonal antibodies for their
Figure 10. Viral transactivation can be neutralized by monoclo-
nal antibodies in MRC-5 and Jurkat cells. (A) MRC-5 cells were
transiently transfected (Lipofectamine 2000 CD) with the pTA-Control
plasmid. Cells were infected with HCMV-HB5 (left panel) or HSV-1 strain F
(right panel). Replication competent virus (black bars) was compared
with UV-inactivated virus (hatched bars). HCMV was incubated for 1 h at
37uC beforeinfectionwith 25 mg/ml of theHCMV gB-specificmonoclonal
antibody ITC88 and HSV-1 with the HSV-1 gD-specific monoclonal
antibody HD1 before infection. Cells were lysed and luciferase activity
was determined. (B) Jurkat cells were transfected with pTA-Control
plasmid using the Lonza transfection reagents and protocol. Cells were
infected with UV-inactivated HSV-1 strain F (hatched bar), replication
competent HSV-1 (black bars) or left uninfected (white bar). Virus was
incubated before infectionfor 1 h at 37uC with indicated dilutions of HSV
gD monoclonal antibody HD1. ,20 h p. i. cells were lysed and the
expressed luciferase activity was measured.
doi:10.1371/journal.pone.0014532.g010
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types. The test can easily be used to analyze whether or not
patients mount an effective neutralizing antibody response toward
HSV-1 or HCMV. Additionally, the test could also be used to
screen and analyze small molecular compounds for their ability to
block HSV-1 and HCMV entry and fusion even in automated
large scale screening approaches. Although not tested so far, it is
tempting to speculate that other herpesviruses might share the
capability to transactivate the responsive element and that it might
thus be instrumental for the assessment of infection and
neutralization of other human and non-human herpesviruses.
For HSV, transactivation-based entry and neutralization assays
have been described [34–36], although in some reports composite
responses have been measured, since transactivated promoters
were combined with virus-driven reporter genes (lacZ) [34,36]. To
our knowledge, no such assay was available for HCMV until now.
In basic research such an assay system can be used for the
assessment of the contribution of viral entry receptors and their
ligands to HSV-1 or HCMV entry and fusion, e. g. UL128-131
[37]. Additionally, the ability of viral Fcc-receptors encoded by
HCMV [38–41] and HSV-1 [42,43] to antagonize neutralizing
antibodies can be studied. An obvious advantage of a cellular-
intrinsic reporter system over a virus-driven one is the chance to
work with unmodified viruses like clinical isolates, which in the
case of HCMV clearly differ from cell-culture adapted viruses and
the opportunity to directly compare sets of virus mutants with a
common reporter system.
Since the identified herpesvirus responsive genetic element is
silent in different cell types and cell lines and does not react on
proinflammatory stimuli elicited by infection with UV-inactivated
virus, even sophisticated experiments could be designed which
would allow probing herpesvirus infection in vivo. It is tempting to
speculate that transgenic animals like mice harbouring such a
genetic element in front of reporter genes encoding for fluorescent
proteins (i.e. eGFP or dsRed) or b-Gal in the rosa26 locus would
not only constitute a perfect sentinel mouse for animal facilities but
also allow delineation of herpesvirus infected cells in vivo.
Materials and Methods
Cells and cytokines
Human MRC-5 lung fibroblasts passage 7–13 (ATCC CCL-
171), human WI-38 fibroblasts (ATCC CCL-75), human HeLa
(ATCC CCL-2), human retinal pigmented epithelium ARPE-19
(ATCC CRL-2302), African green monkey CV-1 (ATCC CCL-
70), mouse M2-10B4 (kindly provided by Brendan Marshall
[Medical College of Georgia, USA]) and Vero cells (ATCC CCL-
81) were grown in Dulbecco’s modified Eagle medium (D-MEM)
supplemented with 10% (vol/vol) foetal bovine serum, streptomy-
cin, penicillin and 2 mM glutamine. Jurkat cells (ATCC TIB-152)
were maintained in RPMI media supplemented with 10% (vol/
vol) foetal bovine serum, streptomycin, penicillin, 100 mM sodium
pyruvate and 2 mM glutamine. Stable cell clones were selected
using 250 mg/ml G418, GIBCO, Invitrogen. Human IFN-c was
purchased from PBL Biomedical Laboratories (New Jersey, USA).
Cells were treated for 5 h with 500 U/ml. TNF-a and IL-1b were
purchased from R&D Systems.
Plasmids and transfection
The plasmids pTA-Control and pTA-GAS are part of the
Mercury Pathway Profiling Luciferase Systems 5; catalogue
number K2057-1 (lot# 2060828) (Clontech, Mountain View,
USA). The plasmids were amplified in E. coli and DNA was
prepared using a midi plasmid preparation kit (Qiagen, Hilden,
Germany). The correct sequence of the minimal promoter pTA-
Control was confirmed by DNA-sequencing (data not shown). The
66 kB-Luc NF- kB-reporter construct has been kindly provided
by Klaus Schulze-Osthoff, Tu ¨bingen, Germany and has been
described previously [44]. pB45Neo has been described [27]. For
the generation of pB45Neo-promLuc, the intrinsic Mth-promoter,
the intron and the poly-adenylation site sequences were excised by
XbaI-BamHI double-digest. The promoter and the luciferase gene
were excised from pTA-Control using NheI (cohesive end to XbaI)
and BamHI and the insert was ligated into the cleaved pB45Neo.
Transfections were done transiently with 6 ml Lipofectamine
2000 CD reagent (Invitrogen, Carlsbad, USA) per 5610
5 cells or
with the Lonza nucleofection electroporation method following
manufacturer’s instructions (Lonza, Cologne, Germany). MRC-5
cells were transfected using kit R (program X-001). WI-38 cells
were transfected using Kit R (program V-001). Primary embryonic
mouse fibroblasts were transfected using kit MEF2 (program A-23)
and kit V was used for other cell types (programs as recommended
by manufacturer). HeLa cells were transfected with Superfect,
Qiagen, Hilden, Germany following manufacturer’s instructions.
2.5 mg plasmid DNA was transfected per 5610
5 cells using the
Lipofectamine transfection protocol. For nucleofection 2.5 mg per
10
6 cells were used.
Viruses and infection conditions
Purified stocks of HCMV strains AD169 [45], Towne (ATCC
VR-977), the BAC-derived HB5 [46] and the BAC-derived
endotheliotropic strain TB40/E [47] were used. Purified stocks of
wt-MCMV strain Smith , MCMV:gfp and Dm157-MCMV:lucifer-
ase were used. MCMV:gfp has been described [48]. Dm157-
MCMV:luciferase was kindly provided by Elke Bleifuss, HHU
Du ¨sseldorf, Germany. Purification was modified based on the
method by [49] as described previously [50]. Infection was
amplified by centrifugal enhancement at 800 g for 30 min at room
temperature. The HSV-1 strain F was kindly provided by David
Johnson (Portland, USA). Infections were done with a multiplicity
of infection of 3 PFU/cell if not indicated otherwise. The low-
passage clinical HSV-1 isolate was isolated from a healthy
individual during characteristic reactivation (cold sore) and
expanded once in cell culture. Crude stocks of VSV have been
used and titrated by TCID50 determination on Vero cells.
Neutralization, antibodies, serum
For neutralization experiments the virus was incubated with the
indicated amount of monoclonal antibody, serum or IVIG for
1.5 h at 37uC in equal volumes of cell culture medium prior to
infection of cells, which have been transfected before as described
above. 20 h post infection luciferase activity was measured if not
indicated otherwise. The IVIG preparation CytotectH was a
generous gift from Biotest (Dreieich, Germany) and concentrations
were used as indicated. Of the human monoclonal anti-HCMV
glycoprotein B (gB) antibody ITC88 (IgG1) ([32]) a concentration
of 25 mg/ml was used in neutralization assays. The monoclonal
HD-1 antibody (IgG2a), directed against HSV-1 glycoprotein D
(gD), kindly provided by Gabriella Campadelli-Fiume (University
of Bologna, Italy), was used at the indicated dilutions. Human sera
were kindly provided by Ortwin Adams, HHU Du ¨sseldorf,
Germany. Usage of human sera for virus neutralization tests was
approved by the ethical committee of the HHU Du ¨sseldorf,
Germany (#3414/2010). Collection of MCMV-specific latency
sera was approved by the respective federal office (LANUV NRW;
reference 50.05-240-61/06).
In the classical HSV-1 neutralization test, serial dilutions of
IVIG were incubated for 1.5 h at 37uC in cell culture medium
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Afterwards CV-1 cells, grown to confluence in 48-well plates, were
overlaid with the dilutions. After 36 h of incubation, virus-plaques
were counted by microscopic inspection. The experiments were
performed in quadruplets, shown is the arithmetic mean 6
standard deviation. The calculated serum dilution inhibiting virus
infectivity by 50% in comparison to untreated virus controls was
indicated as the neutralizing-antibody titre. For a reasonable
failure assessment we calculated the 50% neutralization rate based
on a curve derived from the minimal or the maximal values of the
quadruplet measurements of each antibody dilution, respectively.
The curve leading to a higher deviation was used to calculate the
depicted error of the 50% neutralization rate.
Luciferase Assay
Luciferase activity was measured according to manufacturer’s
instructions (Roche, Mannheim, Germany) using a microplate
luminometer (model LB 96V; Berthold).
Immunoblotting
Immunoblotting was performed according to standard proce-
dures. Briefly, luciferase assay lysates were prepared as described
by the manufacturer (Roche, Mannheim, Germany). Lysates were
subdivided, one aliquot was used to measure the luciferase activity
and the other was used to determine pp72-IE1 and b-actin protein
amount by immunoblotting. Proteins were separated by SDS-
PAGE, transferred to nitrocellulose membranes and probed with
anti-pp72-IE1 (Chemicon, Temecula, USA) and b-actin antibod-
ies (Sigma-Aldrich, Taufkirchen, Germany) followed by a
peroxidase-coupled goat anti-mouse secondary antibody (Dianova,
Hamburg, Germany). Finally, proteins were visualized using the
ECL-Plus chemiluminescence system (GE Healthcare, Munich,
Germany).
Southern blotting
Southern blotting was done following standard operation
procedures with a nick translated DIG-labelled pTA-Control
plasmid. Labelling was performed with the DIG-High Prime Kit
(Roche, Mannheim, Germany) following manufacturers instruc-
tions.
Analysis of IRF-3 dimerization and IFN-b induction
Analysis of IRF-3 dimerization by native sodium-deoxycholate-
PAGE and RT-PCR for IFN-b and GAPDH were performed as
described elsewhere [51]. Briefly, cells were lysed and total RNA
was prepared using the RNeasy Mini kit together with the
QIAShredder columns (Qiagen, Hilden, Germany). Semi-quanti-
tative RT-PCR was performed using the OneStep RT-PCR kit
(Qiagen, Hilden, Germany) using the following primers: 59-
ACCACAGTCCATGCCATCAC-39 and 59-TCCACCACCC-
TGTTGCTGTA-39 for GAPDH. 59-CTTTGCTCTGGCACA-
ACAGGTAG-39 and 59-AGGATTTCCACTCTGACTATG-
GTC-93 for IFN-b.
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